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Abstract
The gene and protein expression profiles in myeloproliferative neoplasms (MPNs) may
reveal gene and protein markers of a potential clinical relevance in diagnosis, treatment and
prediction of response to therapy. Using cDNA microarray analysis of 25,100 unique genes,
we studied the gene expression profile of CD34+ cells and granulocytes obtained from
peripheral blood of subjects with essential thrombocythemia (ET), polycythemia vera (PV)
and primary myelofibrosis (PMF). The microarray analyses of the CD34+ cells and granulo-
cytes were performed from 20 de novo MPN subjects: JAK2 positive ET, PV, PMF subjects,
and JAK2 negative ET/PMF subjects. The granulocytes for proteomic studies were pooled
in 4 groups: PV with JAK2 mutant allele burden above 80%, ET with JAK2 mutation, PMF
with JAK2 mutation and ET/PMF with no JAK2 mutation. The number of differentially regu-
lated genes was about two fold larger in CD34+ cells compared to granulocytes. Thirty-six
genes (including RUNX1, TNFRSF19) were persistently highly expressed, while 42 genes
(including FOXD4, PDE4A) were underexpressed both in CD34+ cells and granulocytes.
Using proteomic studies, significant up-regulation was observed for MAPK and PI3K/AKT
signaling regulators that control myeloid cell apoptosis and proliferation: RAC2, MNDA,
S100A8/9, CORO1A, and GNAI2. When the status of the mTOR signaling pathway related
genes was analyzed, PI3K/AKT regulators were preferentially up-regulated in CD34+ cells
of MPNs, with down-regulated major components of the protein complex EIF4F. Molecular
profiling of CD34+ cells and granulocytes of MPN determined gene expression patterns
beyond their recognized function in disease pathogenesis that included dominant up-regu-
lation of PI3K/AKT signaling.
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Introduction
Myeloproliferative neoplasm (MPN) is a group of stem/progenitor cell-derived clonal disorders
with defective regulation of myeloid cell proliferation, explained by an overproduction of
mature blood cells. The classic BCR/ABL-negative MPNs include polycythemia vera (PV),
essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Their molecular patho-
genesis has been associated with an acquired gain-of-function mutations, majority in the Janus
kinase 2 (JAK2) activating the JAK/STAT pathway [1,2]. JAK2V617Fmutation was linked to
significantly augmented levels of phosphorylated STAT5 and AKT in bone marrow hemato-
poietic cells [3]. The AKT, downstream of phosphoinositide-3-kinase (PI3K), is a key regulator
of cell survival, proliferation and differentiation, and has been found dysregulated in various
cancer cells [4]. The main target of activated AKT was the serine/threonine kinase mammalian
target of rapamycin (mTOR). JAK inhibition abolished phosphorylation of JAK/STAT and
PI3K/mTOR pathway members in acute lymphoblastic leukemia (ALL), suggesting an inter-
connection between these signaling networks [5]. PI3K/mTOR inhibition induced a positive
feedback response that lead to the activation of JAK2/STAT5 (restores pAKT), consequently
diminishing the reaction of the PI3K inhibitors [6]. PI3K/AKT/mTOR inhibitors induced cell-
cycle growth arrest, apoptosis and blocked colony development from MPN hematopoietic pro-
genitors, whereas co-treatment with JAK2-inhibitors synergistically induced apoptosis of the
primary CD34+ MPN cells and significantly reduced erythropoietin-independent colony
growth in patients with PV [7,8].
Categorizing a specific gene signature may provide new insights into pathogenesis of MPN.
Previous studies were focused on various cells to examine gene expression profile in MPN:
whole blood [9,10], CD34+ cells [11–13], granulocytes [11,14–18], and bone marrow
CD34-derived megakaryocytic cells [19]. Some studies described a general gene expression
profile in MPNs [9,10], while others were concentrated into PV [12–15,18], ET [16,17,19] or
PMF [11,12]. A few studies explored the gene expression profile of JAK2 mutation positive and
negative subjects only in ET [9,16,17]. Microarray analyses have been performed on MPN sub-
jects with cytoreductive therapy [9,10,14], de novo MPN subjects [13,16] and combined
[12,19]. Serum proteome of ET subjects was not influenced by the presence of JAK2V617F, as
determined by mass spectrometry-based analysis of serum protein profiles [20]. Moreover, the
proteomic screening of granulocyte proteins fromMPN subjects, showed differential expres-
sion of 60 proteins in PV and ET [21].
Previous microarray and proteomic studies did not represent an overview of all types of
MPN in correlation to JAK2V617Fmutation, and did not explore primitive and mature hemato-
poietic cells simultaneously. To compare these diversities, we combined extensive gene expres-
sion and proteomic profiling in CD34+ cells and granulocytes from JAK2 mutation positive
MPN (PV, ET and PMF) and JAK2 negative MPN (ET and PMF) subjects. Furthermore, we
focused the gene expression profiling to the mTOR signaling pathway in MPN. Since the aber-
rant activity of the PI3K/AKT/mTOR pathway was commonly observed in cancers, and mTOR
inhibitors were used in clinical trials, our current comprehensive results offer an opportunity to
discern the molecular mechanism involved in inhibition of the signaling pathway in MPN.
Materials and Methods
Isolation of CD34+ cells and granulocytes from the peripheral blood of de
novo MPN subjects
Written informed consent was obtained from all patients being included in the study. All
patients had signed the consent form approved by the ethical committee, Faculty of medicine,
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University of Belgrade. All study de novo MPN patients were subject to 30 ml of peripheral
blood draw on one occasion, collected in 10% sodium citrate. The maximum time interval
between venepuncture of patients and samples arrival in the laboratory was 2 hours. Each 30
ml of diluted lymphocytes and other mononuclear cells (1:1,2 ratio of blood with Ca2+/Mg2+-
free PBS) was then layered gently on top of 15 ml lymphocyte separation medium (LSM, PAA
Laboratories GmbH, Pasching, Austria). After centrifugation (400g, 30 min, 20°C), the inter-
face containing mononuclear cells was collected and washed with PBS. The CD34+ cells have
been isolated from the collected mononuclear cells using a magnetic separation column (Super
Macs II, Miltenyi Biotec, Bergisch Gladbach, Germany) and a mixture of magnetic microbeads
conjugated with an antibody against CD34 (Miltenyi Biotec) according to the manufacturer's
instructions. The formed pellet, during centrifugation with LSM, was comprised mostly of
erythrocytes and granulocytes that migrated through the gradient. Contaminating erythrocytes
were removed by lysing solution (0.15 M NH4Cl, 0.1 mM Na2EDTA, 12 mMNaHCO3). High
quality of purified granulocytes was confirmed by cytospin preparations and Wright–Giemsa
staining. The viable CD34+ cell and granulocyte counts were performed with the use of a try-
pan-blue exclusion technique (BioWhittaker). The purity of recovered cells was determined by
flow cytometry using PE–anti-CD34 mAb (BD Biosciences, San Jose, CA, USA) and was over
80% in samples for microarray analysis. Karyotype analysis did not show any chromosome
aberrations in samples for microarray analysis.
Isolation of total RNA
We used RNeasy protocol for isolation of total RNA from CD34+ cells and granulocytes
according to the manufacturer's instructions (Qiagen GmbH, Hilden, Germany). Concentra-
tion and integrity of total RNA was assessed using NanoDrop spectrophotometer (Thermo
Fisher Scientific Inc., Wilmington, Delaware, USA) and Agilent 2100 Bioanalyzer Software
(Agilent Technologies, Waldbronn, Germany) comparing the ratio of 28S and 18S RNA peaks
to ensure that there was a minimal degradation of the RNA sample.
DNA sequencing
Genomic DNA was extracted from peripheral blood granulocytes of MPN subjects by using
the proteinase K and phenol-chloroform technique. Single nucleotide mutation JAK2V617F
was characterized by DNA sequencing after PCR amplification. PCR amplification was per-
formed with wild-type JAK-2-specific forward primer 50- tggcagagagaattttctgaact -30 and
reverse primer 50- ttcattgctttcctttttcaca-30, confirmed by electrophoresis on an ethidium bro-
mide–impregnated 1% agarose gel. PCR amplified samples were analyzed by sequencing on an
automated ABI PRISM 3130 Genetic Analyzer (Applied Biosystems; Life Technologies, Carls-
bad, CA, USA) with AB DNA Sequencing Analysis Software (v5.2) by using the Big Dye Ter-
minator v3.1 Ready Reaction Cycle Sequencing Kit.
Isolation of proteins from granulocytes of MPNs
For protein isolation, we formed four groups of de novo MPN subjects: PV with JAK2V617F
mutant allele burden above 80% (6 subjects: per 3 females and males, average age 60), ET with
JAK2 mutation (5 subjects: 4 females and 1 male, average age 49), PMF with JAK2 mutation (6
subjects: 4 females and 2 males, average age 66) and ET/PMF with no JAK2 mutation (Mut0, 7
subjects: 4 females and 3 males, average age 47). A cold lysis buffer (50 mM Tris pH 7.5, 150
mMNaCl, 1% NP-40, 2mM EDTA, 50 mMNaF) was prepared in advance with protease inhib-
itors (1 mM PMSF, 10 mM ε-aminocaproic acid, 2 μg/ml aprotinin, 50 μg/ml leupeptin, 1 μM
pepstatin A) and Na-orthovanadat (1 mM). The granulocytes of MPN subjects were washed
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twice with PBS and resuspended in 10ml cold PBS with 2 mM EDTA and 1 mMNa-orthova-
nadat (centrifugation 10 min, 1500 rpm). The cell pellet was dried by inverting over paper
towel, vortexed and placed on ice. The cold lysis buffer (with protease inhibitors) was added to
the cell pellet, vortexed and placed in refrigerator for 30 min incubation. The cell suspensions
were removed in prechilled eppendorf tubes, centrifugation 10000g for 15 min at 4°C. The
supernatant was than transfered to a cold eppendorf, mixed and aliquoted into prechilled small
eppendorf tubes and frozen at -70°C.
Protein quantification
Quantification of proteins isolated from granulocytes of MPN subjects was performed using
8-plex iTRAQ (Applied Biosystems). First, the same quantity of protein was taken from each
patient to obtain four groups of MPN, with a mixture of 250μg. After tryptic digestion over-
night, each sample was split in duplicate leading to 8 aliquots. 100μg of each aliquot was labeled
according to the manufacturer’s instructions. The individually labeled digests were then com-
bined into a single sample mixture and subjected to off gel separation (off gel 3100 Agilent)
and desalted on micro spin-columns C18 (Harvard Apparatus) before mass spectrometry anal-
ysis. The peptide mixtures were analysed by nano-LC-MS/MS using an ultimate3000 system
(Dionex, Amsterdam, The Netherlands) coupled to an LTQ-Orbitrap Velos mass spectrometer
(Thermo Scientific, Bremen, Germany). The LTQ-Orbitrap operated in data-dependent acqui-
sition mode with the Xcalibur software. Survey scan MS spectra were acquired in the Orbitrap
on the 300–2000 m/z range with the resolution set to a value of 60,000. The five most intense
ions per survey were selected for CID fragmentation, and the resulting fragments were analysed
in the linear trap (LTQ). Dynamic exclusion was used within 60 seconds to prevent repetitive
selection of the same peptide.
Database search and data analysis
The Mascot Daemon software (version 2.3.0, Matrix Science, London, UK) was used to per-
form database search in batch mode with all the sample raw files. The following parameters
were set for creation of the peak lists: parent ions in the mass range 400–4500, no grouping of
MS/MS scans, and threshold at 1000. A peak list was created for each sample analysed, and
individual Mascot searches were performed. Data were examined alongside homo sapiens
entries in Uniprot protein database (http://www.uniprot.org/). Protein hits were automatically
validated if they satisfy one of the following criteria: identification with at least one top ranking
peptide with a Mascot score of more than 39 (p-value< 0.001) or at least two top ranking pep-
tides each with a Mascot score of more than 22 (p-value< 0.05). When several proteins
matched exactly the same set of peptides, only one member of the protein group was reported
in the final list. To evaluate the false positive rate in these experiments, all the initial database
searches were performed using the "decoy" option of Mascot. For quantification of peptide, the
intensity of reporter ions (m/z: 113; 114; 115; 116; 118; 119 and 121) was divided by the inten-
sity of the reporter ion (m/z: 117) for each measured compound. All ratios were normalized
against the median intensity of reporters. Only proteins quantified with at least two peptides
ratio for each condition were validated. Ratio were transformed into natural logarithms and
plotted against the number of peptides subjected to MS/MS analysis. Gaussian curves were fit-
ted on the smoothed histograms. Proteins with natural log-transformed ion ratios differing by
at least 2×SD (95% confidence) were considered significantly different from the random varia-
tion. Student t test was performed for comparison of ratio corresponding to each replicate (i.e.
116/117 vs. 121/117). Only proteins without a significant difference between the replicates
were maintained for comparison between subgroups of patients.
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Microarray analysis
The human oligo probe set was purchased from Operon Human Genome Array-Ready Oligo
Set Version 4.0 (Eurofins MWGOperon, Huntsville, AL, USA) which contained 35,035 oligo-
nucleotide probes, representing approximately 25,100 unique genes. The human version 4.0
was constructed based on the Ensembl human database build (NCBI-35c), with a full coverage
on NCBI human Refseq dataset. The arrays were produced in house at the Center for Biologics
Evaluation and Research, U.S. Food and Drug Administration by spotting oligonucleotides on
poly-L-lysine coated glass slides by Gene Machines robotics (Omnigrid, San Carlos, CA). The
MIAME (minimum information about a microarray experiment) guideline was adopted for
the data presentation. Total human universal RNA (HuURNA, BD Biosciences, Palo Alto, CA)
served as a universal reference control in the competitive hybridization. Also, our prior experi-
ence with primary cell cultures includes quantitative PCR with housekeeping genes (S16 and
HPRT) to establish similar efficiency of cDNA synthesis and PCR (data not shown). In micro-
array studies, for determination of gene expression in CD34+ cells of:
- PV origin with JAK2 mutation, we used 7 biological and 2 technical replicates (3 females
and 4 males, average age 62);
- ET origin with JAK2 mutation, we used 5 biological and one technical replicate (5 females,
average age 59);
- PMF origin with JAK2 mutation, we used 3 biological and one technical replicate (3
females, average age 72);
- ET/PMF origin with no JAK2 mutation (Mut0), we used 5 biological replicates (3 females
and 2 males, average age 53).
For determination of gene expression in granulocytes, we used per two biological replicates
of ET and PMF origin with JAK2V617Fmutation (4 females, average age 66), three biological
replicates of PV origin with JAK2V617Fmutation (2 females and 1 male, average age 70), and
for Mut0 group (ET and PMF origin without JAK2V617F) we used per two biological and tech-
nical replicates (1 female and 1 male, average age 51). The biological replicates measure a quan-
tity from different donors, while the technical replicates represent RNA samples from one
donor hybridized by multiple arrays (independently labeled aliquots from a single RNA sam-
ple). CD34+ cells yielded lower amounts of total RNA, insufficient for microarray analysis.
Therefore, we amplified total RNA using the Amino Allyl MessageAmp II amplified RNA
(aRNA) Amplification kit (Life Technologies Corp., Carlsbad, CA, US). This amplification pro-
tocol was performed both in CD34+ cells and granulocytes of MPN subjects, for parallel stud-
ies, according to the manufacturer's instructions and using 300 ng of total RNA for
amplification. For microarray analyses we used 3 μg of amplified RNA. Labeled cDNA probes
were produced as described [22]. The prepared hybridization mixture of cDNA probe and
aRNA was added on the array in slide and placed in MAUI hybridization chamber (BioMicro
Systems, Inc., Salt Lake City, UT, USA) and incubated overnight at 42°C. Data Filtration, nor-
malization, and analysis were performed as already described [22]. The microarray data were
available from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession no.
GSE55976). Within each group the average correlation was high: PV– 0.91; ET– 0.87; PMF–
0.75; Mut0–0.78 (S1 Table). The correlation was also very high for examined technical repli-
cates of CD34+ cells—above 0.92. Also, the average correlation coefficient was high among
MPN samples in granulocytes: PV– 0.96; ET– 0.98; PMF– 0.74; Mut0–0.96 (not shown).
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Statistical analysis
For microarray data management and analysis, we used NCI/CIT microArray database
(mAdb) system. The one way ANOVA was applied using mAdb software for measurement of
statistical significance in gene expression among MPN. For mAdb hierarchical clustering we
used uncentered correlation with a modified Pearson correlation equation that assumes the
means are 0.
Results
Gene expression in CD34+ cells and granulocytes of MPN
Reversibly transcribed amplified mRNAs from circulating CD34+ cells and granulocytes of de
novo MPN subjects (labeled with Cy5 dye) and cDNA derived from HuURNA (labeled with
Cy3 dye) were mixed and hybridized with oligonucleotide in microarrays. Results were ana-
lyzed for gene expression. The total number of expressed genes in MPNs was presented in
Table 1 (first column, after 50% filtering). The total gene expression was about two fold larger
in CD34+ cells compared to granulocytes. A total of 87 genes were highly overexpressed (four-
fold and higher compared to HuURNA) in ET, 84 genes in PV, 68 in PMF with JAK2V617F
mutation and 42 genes in ET/PMF JAK2V617F negative (Mut0)-derived CD34+ cells, while in
granulocytes even higher quantity of overexpressed genes were observed (Table 1). Out of that,
we made a list of 94 and 68 common highly up-regulated and defined genes in CD34+ cells and
granulocytes of MPNs, respectively (S2 Table). The 36 genes were persistently highly up-regu-
lated both in CD34+ cells and granulocytes: runt-related transcription factor 1 (RUNX1),
tumor necrosis factor receptor superfamily 19 (TNFRSF19), STE20-related kinase adaptor beta
(STRADB), synuclein beta (SNCB, S2 Table). In addition, we presented a list of 101 and 60
common highly down-regulated and defined genes in CD34+ cells and granulocytes, respec-
tively (S3 Table). Forty-two genes were persistently highly down-regulated both in CD34+ cells
and granulocytes: forkhead box D4 (FOXD4), phosphodiesterase 4A, cAMP-specific (PDE4A,
S3 Table).
Distribution and overlapping of gene expression in CD34+ cells and granulocytes, of MPNs,
have been demonstrated by Venn diagram (Figs 1 and 2). According to Venn diagram, the
genes exclusively overexpressed (not even sporadic after 50% filtration) in CD34+ cells of PV
(ALAS2, FYB, TBXAS1) and ET (HYI, DENND1C) origin were presented in table of Fig 1. The
genes only present and up-regulated in CD34+ cells of JAK2V617F positive PMF origin were:
TPSG1, LRRC27,MAPT, while down-regulated were: SPSB1, DLX4, TSPAN4, and GNL1. The
genes solely up-regulated in CD34+ cells of JAK2V617F negative ET/PMF origin were CEP95,
PTBP2, while down-regulated were CNOT2 and FN1 (Fig 1). In addition, the genes exclusively
overexpressed in granulocytes of ET (MUC2), PV (INPP5K) and PMF (PYCARD) origin were
presented in table of Fig 2.
Expression of genes that regulate myeloid cell proliferation,
differentiation and apoptosis
In accordance with highly up-regulated and down-regulated genes (S2 and S3 Tables), we ana-
lyzed genes that regulate myeloid cell proliferation, differentiation and apoptosis in CD34+
cells and granulocytes of MPNs. Expression of myeloid differentiation stimulating genes were
up-regulated for: RUNX1, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN),
hematopoietic cell-specific Lyn substrate 1 (HCLS1); as well as myeloid differentiation inhibit-
ing genes such as Kruppel-like factor 13 (KLF13) and nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (NFKBIA) in MPNs (Table 2). Among up-regulated
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genes that stimulates cell proliferation were MAS1 oncogene (MAS1), ras-related C3 botuli-
num toxin substrate 2 (RAC2) and signal transducer and activator of transcription 1 (STAT1);
as well as those that inhibits cell proliferation: retinoic acid receptor responder 3 (RARRES3),
and transducer of ERBB2 1 (TOB1, Table 2). Expression of apoptosis-stimulating genes S100
calcium binding protein A8 (S100A8) and TNFRSF19 was up-regulated, as well as the expres-
sion of apoptosis-inhibiting genes NLR family apoptosis inhibitory protein (NAIP, absent in
PMF) and tumor necrosis factor, alpha-induced protein 3 (TNFAIP3). Inhibition of apoptosis
can be achieved via the PI3K/AKT pathway, stimulated by up-regulated coiled-coil domain
containing 88A (CCDC88A) and coronin 1A (CORO1A) genes, while inhibited by up-regulated
KLF13 gene in CD34+ cells and granulocytes of MPNs (Table 2). The MAPK pathway played a
critical role in regulation of cell proliferation [23]. MAPK pathway was stimulated by up-regu-
lated chemokine (C-X-C motif) receptor 4 (CXCR4), growth arrest and DNA-damage-induc-
ible, beta (GADD45B) andMAPK10 genes expression. In addition, MAPK pathway was
inhibited by up-regulated dual specificity phosphatase 1 (DUSP1) and protein tyrosine phos-
phatase, receptor type J (PTPRJ) genes (Table 2).
Statistical analysis of gene expression in MPNs determined by
microarray analysis
We examined the gene expression in CD34+ cells and granulocytes of JAK2V617F positive and
negative MPN subjects. We determined significantly different genes among MPNs in CD34+
cells (p<0.01, Table 3). In addition, these significant genes were also shown in hierarchical
clustering analysis to illustrate their associations (Fig 3). A significant gene overexpression was
observed for CRIP1 and GADD45B in JAK2 positive ET subjects, while GLRX, IFI16 and
LAMP1 were over-expressed in PV subjects. In JAK2 positive PMF subjects a significant gene
overexpression was observed for CPNE3, APEX1 and KDM1A, while in JAK2 negative MPN
subjects were over-expressed CIB1, NBPF10 and GPR160 (Table 3, Fig 3). Also, the array clus-
tering of significant genes was in accordance with examined MPN groups, except one
JAK2V617F positive ET sample mixed with Mut0 group that contained JAK2V617F negative
ET patients (Fig 3). In granulocytes of JAK2 positive MPN subjects a significant gene over-
expression was determined for phosphoribosyl pyrophosphate synthetase-associated protein
Table 1. Total number of genes and quantification of highly up-regulated and down-regulated genes versus HuURNA in MPNwith or without
filtering.
Filtering >50%
Cells MPN total 2–3 fold 3–4 fold  4 fold
UR DR UR DR UR DR
CD34+ ET 4921 380 252 85 101 87 21
PV 5522 459 233 117 117 84 38
PMF 4277 227 365 48 81 68 5
Mut0 4744 267 198 54 79 42 68
Granulocytes ET 2059 297 352 145 20 149 0
PV 2050 354 398 164 14 131 0
PMF 2485 233 365 108 81 52 5
Mut0 1538 215 305 98 36 118 1
UR—up-regulated and DR—down-regulated genes
doi:10.1371/journal.pone.0135463.t001
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(PRPSAP2), myosin VIIB retinoblastoma-like 2 (RBL2), S100A9, and microRNA 424 genes
(MIR424, S4 Table).
Proteomic analysis of granulocytes in MPNs
It has been analyzed protein expression in granulocytes and the corresponding gene expression
in circulating CD34+ cells of MPN subjects (Table 4). The common and statistically significant
tendencies at mRNA and protein levels, in MPNs ratio, were demonstrated for the following
genes: ARP2 actin-related protein 2/3 homolog (ACTR2/3), ATP synthase, H+ transporting
beta polypeptide (ATP5B), carbonic anhydrase I (CA1), filamin A, alpha (FLNA), HSP90AB1,
moesin (MSN), protein disulfide isomerase family A, member 6 (PDIA6), PPPIA, proteasome
activator subunit 2 (PSME2), and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide (YWHAB, Table 4). Contrary, the inverse tendencies in
Fig 1. Comparison of total gene expression in CD34+ cells amongMPNs by Venn diagram after 50% filtration. A) Among JAK2V617F+ ET, PV and
PMF; Among JAK2V617F negative ET/PMF (Mut0) and B) JAK2V617F+ ET and PV; C) JAK2V617F+ ET and PMF; D) JAK2V617F+ PV and PMF.
Table represents the genes exclusively expressed in a single MPN disorder.
doi:10.1371/journal.pone.0135463.g001
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MPNs ratio were demonstrated for annexin A5 (ANXA5), oxidative stress related catalase
(CAT), GDP dissociation inhibitor 2 (GDI2), GLRX, heat shock 70kDa protein 1A (HSPA1A),
keratin 10 (KRT10), lectin galactoside-binding soluble 1 (LGALS1), leukotriene A4 hydrolase
(LTA4H), N-myc downstream regulated 1 (NDRG1), protein tyrosine phosphatase, non-
receptor type 6 (PTPN6), RAB10, RAP2B, S100A4/6, and superoxide dismutase 1 (SOD1)
genes (Table 4). The expanded list of proteins defined by proteomic analysis and correspond-
ing genes defined by microarray in MPNs were presented in S5 Table. Using proteomic studies,
a significant up-regulation was detected for proteins that control myeloid cell apoptosis and
proliferation: RAC2, myeloid cell nuclear differentiation antigen (MNDA), S100A8/9,
CORO1A, guanine nucleotide binding protein α inhibiting activity polypeptide (GNAI2, S5
Table), observed also by microarray analysis (Table 2). All genes defined by MPNs ratio in
proteomic analysis were individually examined by microarray analysis in CD34+ cells and
observed values were presented as mean difference in S6 Table. The following genes had
increased expression both at protein and mRNA levels in JAK2 positive MPN subjects:
ANXA1 in ET and PMF; CAI, charged multivesicular body protein 5 (CHMP5), ficolin 1
(FCN1), major vault protein (MVP) in PV; copine III (CPNE3), formin binding protein 1
(FNBP1), S100A4 in PMF; as well as in JAK2 negative MPN subjects: tropomyosin 3 (TPM3),
CAT, ACTR2, and LTA4H (Table 4). Genes particularly increased at protein level in granulo-
cytes of JAK2 positive MPNs were: ANXA5, KRT10, LGALS1, splicing factor 3b, subunit 2
Fig 2. Comparison of total gene expression in granulocytes amongMPNs by Venn diagram after 50% filtration. A) Among JAK2V617F+ ET, PV and
PMF; Among JAK2V617F negative ET/PMF (Mut0) and B) JAK2V617F+ ET and PV; C) JAK2V617F+ ET and PMF; D) JAK2V617F+ PV and PMF.
Table represents the genes exclusively expressed in a single MPN disorder.
doi:10.1371/journal.pone.0135463.g002
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Table 2. Cell differentiation, proliferation and apoptosis related genes expression in CD34+ cells and granulocytes of MPN subjects.
PV ET PMF Mut0
Genes Cells Mean SD Mean SD Mean SD Mean SD
1 Myeloid cell differentiation
A HCLS1 4A CD34 4.36 0.35 4.28 0.76 3.77 0.10 3.70 0.81
A JAK2 3A, 4A CD34 4.02 0.45 3.54 0.81 3.01 0
A LYN 2A, 4A, 5B CD34 3.81 0.44 3.35 0.95 3.41 0 3.69 0.74
A PTPRC CD34 3.86 0.32 4.55 0 3.68 0 4.34 0
GRA -1.27 0.45 -1.08 0 -2.32 0 -0.27 0
A RUNX1 CD34 4.54 0.45 4.85 0.50 5.34 0.25 4.47 0.35
GRA 5.81 1.05 5.71 0 5.18 0.15 5.74 0
A SPI1 CD34 3.78 0.55 2.92 0.73 3.09 1.34
B KLF13 2B CD34 3.74 0.45 3.15 0.55 2.69 0.17 3.4 0.73
B NFKBIA CD34 3.62 0.73 4.21 1.04 3.34 0.51 3.30 1.10
B NME1 2B CD34 -2.16 0.5 -2.39 0.5 -1.27 0.5 -2.04 0.57
GRA -1.42 0.33 -1.14 0.14 -1.80 0.32 -1.41 0.27
2 Cell proliferation
A CYBA CD34 2.25 0.80 2.68 0.51 1.90 0.16 2.45 0.41
A EIF5A CD34 -2.60 0.20 -2.77 0 -2.13 0.12 -1.81 0.06
A MAS1 CD34 4.12 0.92 5.00 0.77 5.49 0.14 4.95 0.19
A PGF CD34 -3.47 0.49 -2.62 0.55 -3.64 0.95 -2.94 0.78
GRA -1.39 0.16 -1.59 0.10 -2.22 1.25 -0.84 0.52
A PLAC8 3B CD34 2.97 0.68 3.33 0.56 4.20 0
A PRAME 1B, 3B CD34 -3.39 0.32 -3.04 0.46 -3.01 0.21 -2.97 0.42
GRA -1.42 0.01 -1.17 0.03 -2.65 0.75 -1.48 0.35
A PTEN 3B, 4B CD34 3.08 0.26 2.86 0.56 3.01 0.37 2.53 0.78
A PTPRC CD34 3.86 0.32 4.55 0 3.68 0 4.34 0
GRA -1.27 0.45 -1.08 0 -2.32 0 -0.27 0
A RAC2 CD34 3.43 0.29 3.22 0.49 2.97 0.32 3.36 0.46
GRA 0.92 0 3.18 1.62 1.40 0.21
A SAT1 CD34 3.63 0.63 4.12 0.99 1.93 1.17 3.01 0.76
A STAT1 CD34 4.76 0.50 4.68 0.85 4.18 0.39 3.35 1.10
B IL8 CD34 3.73 1.6 3.75 2.11 2.11 2.85 3.84 1.91
GRA 2.76 0 6.16 0 1.52 0.63
B KLF11 3A CD34 2.50 0.14 2.74 1.07 4.09 0 2.14 0
B RARRES3 CD34 3.79 0.57 3.47 0.55 3.44 0.20 3.04 0.12
B RBM5 CD34 3.04 0.18 2.67 0.44 1.94 0 2.4 0.48
B SERPINE2 4A CD34 -3.25 0.74 -3.15 0.55 -3.02 0.54 -2.87 0.62
GRA -1.51 0.12 -2.00 0.16 -3.02 0.54 -1.66 0.52
B SKAP2 CD34 2.86 0.44 3.16 0.74 2.73 0.33 2.59 0.18
B SOD2 CD34 3.02 0.71 3.32 0.52 3.40 0.93 3.50 0.02
GRA 0.24 0.40 -0.15 0 1.7 2.06 0.23 0.27
B TOB1 CD34 2.33 1.09 2.72 1.30 4.15 0.23 2.87 0.63
GRA 3.93 1.61 2.38 0.11 1.26 0.58 2.34 0.86
3 Apoptotic process
A MNDA CD34 4.23 0.36 3.14 0.61
A S100A8 CD34 6.07 0.46 5.67 1.16 6.36 0.17 5.58 0.26
A S100A9 CD34 4.98 0.40 5.14 0.60 4.43 0.62 4.95 0.65
GRA 5.10 0.20 2.04 0.33 5.64 1.53 2.52 1.06
(Continued)
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(SF3B2) in PMF; chitinase 1 (CHIT1), HSPA1A, PSME2 in ET; and chaperonin containing
TCP1, subunit 2 (CCT2) in PV; as well as in JAK2 negative MPN subjects: NDRG1, GDI2, glu-
cose-6-phosphate isomerase (GPI), and PTPN6 (Table 4). In concomitantly analyzed gene
expression in CD34+ cells of MPNs, the following genes showed highly significant (p<0.01)
and increased expression in JAK2 positive MPN subjects: APEX1, chromobox homolog 1
(CBX1), FCN1, TPM3, dihydrolipoamide S-succinyltransferase (DLST), GLRX, malic enzyme
2, NAD(+)-dependent, mitochondrial (ME2), and RAB10. The following genes have increased
expression in JAK2 negative MPN subjects: FNBP1, GNAI2 and proliferation-associated 2G4
Table 2. (Continued)
PV ET PMF Mut0
Genes Cells Mean SD Mean SD Mean SD Mean SD
A TNFRSF19 CD34 2.27 1.08 2.98 1.10 4.11 0.61 2.34 1.34
GRA 4.36 1.04 4.33 0.35 3.59 0.80 4.55 0.43
A TXNIP CD34 2.68 0.70 2.91 0.27 2.34 0 2.31 1.16
B NAIP CD34 2.78 0.62 2.81 0.31 2.37 0.2
B TNFAIP3 CD34 2.57 0.83 2.71 1.13 1.00 0.53 3.18 0.76
4 PI3K / AKT activity
A CCDC88A CD34 4.06 0.64 4.06 0.83 5.32 0 3.35 1.13
GRA 5.02 0.73 4.87 0.05 5.16 0.11 5.08 0.44
A CORO1A CD34 4.15 0.44 4.02 0.52 3.57 0.14 4.01 0.95
GRA 1.28 0.35 0.5 0 3.22 2.52 0.40 0
A SEMA4D 3B CD34 2.76 0.56 2.8 0.94 2.29 0.02 2.11 0.85
B KLF13 2B CD34 3.74 0.45 3.15 0.55 2.69 0.17 3.4 0.73
5 MAP kinase activity
A CCL3 4A CD34 1.81 0.29 3.06 0.77 1.46 0.75 2.37 0.78
GRA 2.65 0.45 2.64 0.07 2.37 0.60 3.02 0.78
A CXCR4 CD34 3.80 0.84 3.37 1.14 3.71 0 3.45 1.08
A FPR1 CD34 4.86 0.48 4.59 1.30
A GADD45B 1A CD34 2.09 0.64 2.97 0.62 1.03 0.98 2.1 0.85
GRA 0.46 0 0.25 0 2.45 1.47 0.75 0
A GNAI2 2A CD34 2.92 0.32 2.89 0.60 2.21 0.34 2.79 0.87
GRA -0.02 0.45 1.26 2.14 -0.87 0
A IGF2 2A, 4A CD34 -3.52 0.57 -3.13 0.45 2.08 1.33 -2.93 0.31
GRA -1.38 0.31 -1.51 0.45 -2.63 0.28 1.75 0.52
A MAPK10 CD34 2.69 0.56 2.67 0.52 2.82 1.08 2.45 1.22
GRA 4.55 0.33 4.72 0.11 4.03 0.56 4.62 0.03
A PYCARD 3A CD34 2.52 0.35 2.94 0.54 2.32 0.073 2.30 0.33
A SSTR4 2B CD34 -3.86 0.39 -4.14 0.52 -4.13 0.81 -3.92 0
GRA -2.85 0 -2.4 0.11 -4.18 0 -1.94 0
A VEGFA 2A, 3B CD34 -2.83 0.55 -2.74 0.59 -2.76 1.25 -2.77 0.81
B DUSP1 3A CD34 4.19 1.05 4.35 0.93 4.85 0 3.66 0.89
B DUSP2 CD34 2.90 0.57 3.00 1.30 2.29 0 3.58 0
B DUSP6 1A, 3A CD34 3.08 0.58 3.33 0.75 2.38 0.69 3.32 0.74
B PTPRJ 4B CD34 3.17 0.64 3.33 1.14 2.18 0 3.62 0.31
Superscripts next to genes correspond also to presented groups (1–5); stimulating (A) and inhibiting (B) factors; GRA—granulocytes.
doi:10.1371/journal.pone.0135463.t002
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Table 3. The statistically significant genes (p<0.01) amongMPNs in CD34+ cells determined by microarray analysis.
Group A—ET Group B—PV Group C—PMF Group D -Mut0
Genes MD BG Mean SD Mean SD Mean SD Mean SD
ABCA7 1.16 A-C -0.54 0.33 -1.47 0.17 -1.67 0.39 -1.04 0.48
ACTL6A 1.86 C-D -0.21 0.15 0.28 0.46 1.38 0.24 -0.48 0.09
AKNA 0.89 A-C -1.04 0.16 -1.59 0.19 -1.93 0.48 -1.09 0.49
AKR7A2 0.69 C-A -0.63 0.14 -0.53 0.18 0.06 0.15 -0.15 0.19
ANXA2 1.22 A-C -1.36 0.38 -1.60 0.35 -2.59 0.57 -1.66 0.25
APEX1 1.32 C-A 1.21 0.38 2.23 0.50 2.54 0.63 1.56 0.08
ATP6V0D1 0.91 D-C 1.55 0.25 1.43 0.22 0.75 0.08 1.67 0.02
BACH1 1.86 D-C 2.79 0.43 2.72 0.51 1.36 0.41 3.22 0.06
BBC3 1.18 A-C 1.13 0.26 0.71 0.42 -0.05 0.37 0.57 0.18
CCDC69 1.51 A-C 2.16 0.44 1.72 0.36 0.65 0.61 1.85 0.04
CCT2 1.93 C-A -0.29 0.61 0.96 0.29 1.63 0.90 0.06 0.39
CEBPD 0.86 A-B 1.43 0.02 0.57 0.09 0.85 0.12
CIB1 1.28 D-C 1.46 0.26 1.09 0.27 0.95 0.23 2.23 0.61
CKS2 1.56 C-A -1.79 0.30 -1.26 0.59 -0.23 0.60 -1.64 0.23
CLDND1 0.88 A-C 1.09 0.36 0.91 0.26 0.21 0.18 0.26 0.22
COX17 0.88 B-C 0.31 0.31 0.66 0.32 -0.22 0.29 0.08 0.17
CPA5 1.28 A-C 1.47 0.26 0.52 0.28 0.20 0.38 0.94 0.57
CPNE3 1.13 C-B 1.42 0.23 1.08 0.17 2.21 0.26 2.26 0.00
CRIP1 1.54 A-C 2.34 0.23 1.46 0.26 0.81 0.22 2.24 0.52
CRIP1 1.57 D-C 1.42 0.53 0.68 0.18 -0.13 0.52 1.44 0.81
CRYZL1 0.93 A-D 1.82 0.01 1.75 0.08 0.89 0.30
CST3 1.59 A-C 1.65 0.28 0.98 0.46 0.06 0.62 1.24 0.34
DCTPP1 1.30 C-A -0.29 0.26 0.06 0.42 1.01 0.59 0.09 0.20
DHX9 0.82 C-A 0.31 0.23 0.94 0.17 1.14 0.35 0.55 0.21
DNAJA1 0.92 B-D 0.45 0.46 0.99 0.41 0.77 0.08 0.07 0.23
DNAJB9 0.85 B-D 1.23 0.10 0.39 0.11
DNMT3A 1.25 C-D 0.19 0.00 1.06 0.25 1.93 0.16 0.68 0.05
DOCK11 0.63 B-C 3.25 0.00 3.28 0.06 2.64 0.10
ECI2 1.17 C-D -0.48 0.04 -0.15 0.26 0.56 0.26 -0.62 0.21
FAM26F 1.99 B-D 3.43 0.68 4.53 0.46 3.22 0.61 2.54 0.38
FBXO3 1.20 B-C 1.17 0.00 1.41 0.29 0.21 0.50 0.53 0.00
FCN1 2.83 A-C 4.66 0.29 4.00 0.28 1.83 1.38 3.84 0.80
FGD2 1.11 A-D 2.23 0.17 1.74 0.27 1.68 0.00 1.12 0.08
GADD45B 2.20 A-C 3.12 0.55 1.98 0.68 0.92 0.82 2.45 0.53
GCSH 1.74 C-A -1.61 0.19 -0.95 0.58 0.13 0.80 -1.14 0.42
GLRX 1.19 B-C 2.21 0.56 2.52 0.42 1.33 0.54 1.47 0.43
GLT8D1 0.97 C-D 0.38 0.12 0.29 0.14 0.70 0.08 -0.27 0.29
GPR160 1.11 D-A 1.16 0.34 1.63 0.23 0.82 0.00 2.27 0.00
HERPUD1 1.73 D-C 1.57 0.36 1.46 0.68 0.19 0.27 1.92 0.30
HNRNPCL1 0.45 B-D -2.62 0.00 -2.27 0.04 -1.76 0.00 -2.72 0.00
HSPD1 1.60 C-A -2.64 0.09 -1.95 0.59 -1.04 0.80 -2.53 0.39
IDH3G 0.72 B-C 0.68 0.00 0.62 0.17 -0.10 0.03 0.44 0.00
IFI16 1.29 B-D 0.16 0.48 0.81 0.40 0.03 0.28 -0.47 0.27
IMPDH2 2.08 C-A -2.20 0.16 -1.52 0.47 -0.12 0.32 -1.74 0.22
INSIG2 0.98 B-D 0.12 0.00 0.82 0.18 0.81 0.16 -0.17 0.19
IQSEC1 2.14 A-C 0.72 0.45 0.09 0.29 -1.42 0.03 0.31 0.31
(Continued)
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Table 3. (Continued)
Group A—ET Group B—PV Group C—PMF Group D -Mut0
Genes MD BG Mean SD Mean SD Mean SD Mean SD
JPH3 0.96 D-B -0.84 0.32 -1.29 0.17 -0.92 0.13 -0.33 0.26
KDM1A 1.39 C-D -0.60 0.00 -0.18 0.35 0.80 0.26 -0.59 0.27
KIAA0930 1.29 A-C 2.84 0.55 2.75 0.52 1.56 0.04 1.81 0.47
LAMP1 1.10 B-D 0.62 0.47 1.33 0.37 1.12 0.08 0.23 0.30
LCE2A 1.28 A-B 0.95 0.43 -0.33 0.30 -0.17 0.58 0.53 0.00
LGALS1 1.55 D-C -1.07 0.37 -1.47 0.26 -2.17 0.48 -0.62 0.43
LGALS3 2.20 A-C -0.37 0.54 -0.62 0.49 -2.57 0.69 -0.42 0.30
LRRC37BP1 0.67 C-A 0.84 0.10 0.93 0.17 1.50 0.05 1.00 0.04
METTL17 0.61 C-D 0.44 0.00 0.49 0.00 1.04 0.03 0.43 0.05
MRPL41 0.78 A-D 0.76 0.24 0.06 0.09 0.14 0.27 -0.02 0.45
MRPL48 1.02 C-D -1.08 0.00 -0.51 0.09 -0.02 0.14 -1.05 0.15
MYL6 1.14 A-C 1.43 0.40 0.68 0.21 0.29 0.24 1.41 0.67
MYL6 1.46 D-C 1.70 0.56 0.82 0.27 0.34 0.34 1.79 0.80
NBPF10 1.56 D-B 2.00 0.99 0.68 0.35 0.70 0.06 2.25 0.86
NCL 1.67 C-A -1.65 0.01 -0.65 0.31 0.02 0.57 -1.11 0.32
NINJ1 1.87 D-C 1.45 0.26 0.89 0.42 0.40 0.86 2.27 0.69
NMI 0.98 B-D 2.75 0.49 3.38 0.27 3.19 0.17 2.40 0.18
NOP58 1.43 C-A -0.19 0.07 0.25 0.32 1.24 0.14 0.38 0.08
P4HTM 0.89 A-D 1.90 0.06 1.15 0.07 1.20 0.00 1.01 0.03
PDLIM5 1.08 B-C 1.96 0.43 2.10 0.29 1.03 0.23 1.64 0.24
PF4V1 1.66 D-B 1.32 0.37 0.31 0.38 0.77 0.00 1.97 0.39
PMS2L2 0.64 A-B 1.17 0.18 0.52 0.19 0.57 0.47 0.86 0.24
PPA2 1.51 C-A -0.55 0.41 0.00 0.36 0.96 0.18 -0.29 0.22
PRDX2 1.08 C-A -2.21 0.36 -1.81 0.19 -1.13 0.37 -1.77 0.18
PRSS57 2.27 C-A -0.87 0.25 -0.28 0.54 1.41 1.08 -0.41 0.06
PSMC6 1.04 C-D -0.09 0.00 -1.01 0.17 -0.86 0.23 -1.90 0.23
PTPLA 1.76 C-D 0.22 0.00 0.95 0.55 2.15 0.03 0.38 0.34
RBMX 1.81 C-A -1.33 0.58 -0.59 0.47 0.48 0.73 -0.47 0.14
RBPJ 0.78 A-C -0.31 0.31 -0.56 0.13 -1.10 0.19 -0.59 0.16
RFFL 0.61 A-D 1.35 0.05 0.80 0.04 1.19 0.00 0.74 0.01
RNF144A 0.89 B-A 0.67 0.27 1.56 0.35 1.44 0.47 1.08 0.21
RSL1D1 0.99 C-A -0.47 0.37 0.16 0.30 0.52 0.09 -0.15 0.26
SAT1 2.33 A-C 2.27 0.22 1.77 0.65 -0.06 0.64 2.01 0.66
SFXN1 0.48 A-B 1.50 0.15 1.02 0.10 1.23 0.01 1.32 0.08
SLC27A3 1.54 A-C 2.91 0.58 2.34 0.30 1.37 0.22 2.08 0.47
SMARCB1 0.50 D-B -0.67 0.00 -0.49 0.20 -0.01 0.04 0.01 0.07
SNTB1 0.62 B-A 1.31 0.26 1.93 0.17 1.04 0.00 0.90 0.00
SNX2 1.05 B-C 1.10 0.05 1.24 0.24 0.19 0.11 0.63 0.32
SPG20 1.26 B-D 1.48 0.18 1.40 0.00 0.22 0.34
STIP1 1.08 C-A -1.59 0.06 -1.65 0.00 -0.51 0.05 -1.85 0.00
SUPT3H 0.64 A-B 1.34 0.22 0.70 0.20 0.78 0.22 1.07 0.35
TMSB10 1.10 B-C -0.97 0.35 -0.88 0.41 -1.99 0.12 -1.07 0.28
TMSB4X 1.62 A-C 2.47 0.34 2.07 0.46 0.86 0.93 2.14 0.31
TSR3 0.38 C-B -0.42 0.00 -0.22 0.01 0.16 0.01 -0.27 0.00
UCHL5 0.84 B-D 0.04 0.00 0.99 0.05 0.86 0.00 0.15 0.24
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(PA2G4, Table 4). Regarding defined genes in granulocytes by proteomic study, the microarray
analyses of them were performed in granulocytes of MPN subjects and presented in S7 Table.
Expression of genes linked to mTOR signaling pathway in MPNs
The activity of PI3K/AKT and mTOR was closely related, and interact with MAPK signaling
pathway [24]. Using microarray analysis, we analyzed mTOR signaling pathway related genes
in CD34+ cells of MPNs as presented in Fig 4. Phosphatase and tensin homolog (PTEN) and
protein kinase C β (PRKCB) had the most elevated expression of examined genes in MPNs,
while PRKCB was significantly more expressed in PV in comparison to JAK2V617F negative
MPN (Fig 4A). Phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and regulatory
subunit 1 (PIK3R1) were only overexpressed in PV subjects, as well as MAPK1. Hypoxia induc-
ible factor α (HIF1α) was significantly more expressed in JAK2 positive ET and PMF subjects
than in other MPN subjects (Fig 4A). Serine/threonine kinase 11 (STK11) gene expression was
significantly up-regulated in CD34+ cells of PV in comparison to JAK2V617F negative MPN
subjects (Fig 4A). The eukaryotic translation initiation factors did not have changed gene
expression (Fig 4B) or were highly down-regulated genes such as eukaryotic translation initia-
tion factor 4E binding protein 1 (EIF4EBP1) and 4γ1 (EIF4G1), as well as vascular endothelial
growth factor A (VEGFA, Fig 4C). EIF4EBP1 and EIF4G1 genes expression were also down-
regulated in granulocytes. EIF4EBP1 and placental growth factor (PGF) gene expression were
significantly more down-regulated in PV than ET subjects, while ribosomal protein S6 (RPS6)
in ET and JAK2V617F negative MPNs (Fig 4C). Overview and connection among examined
mTOR signaling pathway related genes was presented in Fig 5. Most of the genes were up-regu-
lated and expressed in MPNs, while some of them were down-regulated and not detected.
MAPK1 gene expression was increased almost exclusively in PV patients. Major PI3K/AKT
signaling pathway related genes were up-regulated, including ribosomal protein S6 kinase,
90kDa, polypeptide 1 (RPS6KA1) and Ras-related GTP binding A (RRAGA, Fig 5).
Discussion
Using microarray and proteomic analyses, we illustrated a broad gene and protein expression
pattern in MPNs. A two times higher number of genes was detected in primitive CD34+ cells
compared to mature granulocytes of MPNs. In addition to common genes, we observed dis-
tinctive genes for PV, ET, PMF and JAK2V617Fmutation negative MPNs in CD34+ cells.
Proteomic analyses revealed proteins with a statistically significant expression in granulocytes
Table 3. (Continued)
Group A—ET Group B—PV Group C—PMF Group D -Mut0
Genes MD BG Mean SD Mean SD Mean SD Mean SD
UNC93B1 1.84 A-C 3.11 0.47 2.67 0.51 1.27 0.24 2.63 0.73
UQCRC1 0.78 C-B -0.93 0.00 -0.55 0.04 0.23 0.04 -0.02 0.02
YEATS4 1.44 C-D -0.14 0.08 0.28 0.34 0.97 0.33 -0.47 0.17
ZNF189 0.66 C-B -1.38 0.00 -1.95 0.18 -1.29 0.02 -1.36 0.05
ZNF267 0.69 C-A -1.06 0.14 -0.56 0.33 -0.36 0.09 -1.03 0.15
ZNF592 1.15 A-C 2.68 0.40 2.47 0.25 1.54 0.21 2.94 0.00
ZNF876P 0.90 C-A -0.50 0.29 0.14 0.32 0.39 0.29 -0.38 0.24
The negative values represent down-regulated genes, while positive values represent up-regulated genes compared to HuURNA. BG—Between groups
significance with p<0.01, MD—Maximal mean difference of corresponding BG.
doi:10.1371/journal.pone.0135463.t003
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Fig 3. Hierarchical clustering of highly significant genes expressed in CD34+ cells of MPNs. Statistical significance (p<0.01) was determined among
JAK2V617F positive ET (yellow), PV (red), PMF (blue) and JAK2V617F negative ET/PMF (Mut0, green) by one way ANOVA. The numbers on top and below
the color bar represent intensity of contrasts with offsets at 0 and 1. The total gene expression of MPNs is also clustered (above image) representing
similarities among examined cells. The gene and array correlations were uncentered. The gene description is provided in Table 3.
doi:10.1371/journal.pone.0135463.g003
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Table 4. The common statistically significant genes in comparative proteomic (granulocytes) andmicroarray analyses (CD34+ cells).
Ratio PV / ET PV / PMF ET / PMF PV / Mut0 ET / Mut0 PMF / Mut0
Genes P M P M P M P M P M P M
ACTR2 1.06 A1 0.94 0.91 0.94
ACTR3 1.1 A1 0.93 A1 0.92
ALB 0.9 B1
ANXA1 0.95 0.97 1.05 A1 1.09 1.07
ANXA2 A1 0.77
ANXA5 0.89 0.83 0.95 A2 1.16 1.22
APEX1 A2 B1 0.96
ARPC3 A1 0.87
ARPC5 A1 A1 0.96
ATP5A1 A1 0.92
ATP5B 1.08 A1 0.92
ATP6V1E1 1.11 A1
CA1 0.83 1.2 A1 1.44 1.22 1.47
CANX 1.08 A1 A1 0.94
CAT 0.93 A1 0.9 0.97 0.94
CBX3 A2 B1 A1 0.88
CCT2 1.12 A2 0.84 0.86
CHIT1 0.82 B1 1.21 0.89
CHMP5 2.24 A1
CPNE3 B1 B2 0.94 B1 1.08
DDT 1.01 A1 1.02 B1 1.07
DLST A2 0.91
ENO1 0.95 B1 B1
FBP1 B1 1.2
FCN1 1.39 A2 0.74 A1 0.77
FLNA 0.94 B1 0.94 0.94
FNBP1 B2 B1 1.08
GAPDH 0.98 B1 0.94 0.94 B1 0.98
GDI2 A1 0.92 A1 0.94
GLRX 0.91 A1 0.89 A2 1.08
GNAI2 0.92 A1 B2 B2
GPI 1.18 0.81 0.73 0.85 B2 0.76 B1
GSTP1 0.9 0.99 B1 0.94 0.91
H2AFY 0.9 B1
HBD 0.63 A1 1.25 1.82 A1 1.61 0.9
HIST1H2BO B1 0.85 0.84
HSP90AB1 1.08 A1 0.93 0.96
HSPA8 A1 0.98
HSPA1A 0.84 A1 1.15 1.39 1.13 A1 1.35
KRT10 1.45 1.38 0.7 0.55 B1 0.56
LGALS1 0.83 0.64 A2 0.77 A2 0.8 B1 B1 1.3 B1
LTA4H 0.95 0.94 A1 0.94
ME2 0.93 A2
MIF 0.89 B1
MSN 0.92 B2 1.06
MVP 1.2 B1 1.38 1.22
(Continued)
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of MPN subjects in correlation with JAK2V617Fmutation. In CD34+ cells of JAK2 positive ET
subjects, a largely increased gene expression was observed for CRIP1 and GADD45B, in PV
subjects for GLRX, IFI16, LAMP1, in PMF subjects for CPNE3, APEX1, KDM1A, while in
JAK2 negative MPN subjects for CIB1, NBPF10 and GPR160. After hierarchical clustering, the
arrays of statistically significant genes largely demonstrated tendency to stay gathered within
the examined 4 MPN groups. We identified over-expression of genes that regulate myeloid cell
proliferation (MAS1, RAC2), differentiation (RUNX1,HCLS1) and apoptosis (S100A8,
TNFRSF19) of MPNs. Interestingly, a large number of mTOR signaling pathway related genes
was observed in MPNs with up-regulated PI3K/AKT signaling.
Previous profile reports included various quantities of examined genes between 6000 and
14500, from purified primary cells of MPNs [11–19]. We performed parallel proteomic and
microarray studies from the same MPN subjects to strengthen the comparability of a broad
gene expression study with 25,100 genes. Actually, we explored both primitive CD34+ cells and
mature granulocytes, isolated simultaneously from the peripheral blood of MPN subjects, to
illustrate a continuous gene expression profile during hematopoiesis.
The PI3K/AKT/mTOR pathway is commonly activated in human cancers and has a vital
role in cell growth, proliferation, survival, apoptosis, and angiogenesis [25]. The inhibition of
PI3K or mTOR corrected the expansive myelopoiesis in the PTEN-deficient embryos [26]. The
inactivation of PTEN activity was a result of PTEN phosphorylation associated with AKT
phosphorylation and shorter overall survival. PTEN suppressed apoptosis and regulated cell
growth controlling p70 S6 kinase (S6K) in the cytoplasm, while regulated cell cycle progression
in the nucleus [27]. The activity of p70 S6K was controlled by multiple phosphorylation events
Table 4. (Continued)
Ratio PV / ET PV / PMF ET / PMF PV / Mut0 ET / Mut0 PMF / Mut0
Genes P M P M P M P M P M P M
NDRG1 1.17 B1 0.71 0.66 0.88
PA2G4 B1 B1 0.96
PDIA6 1.13 A1
PPIA 0.91 1.13 A1
PPIB 0.74 1.5 B1 1.42 0.94
PSME2 1.23 A2 A1 1.18 A2
PTPN6 0.95 0.93 0.91 A1
RAB10 0.89 A1 A2 A2
RAP2B 0.8 A1
RAB8A 0.9 A1
RHOA 0.95 0.95 0.94 B1
S100A4 0.77 0.8 A1 0.84 1.06
S100A6 0.9 A1
SF3B2 A1 1.18
SOD1 0.91 A1 1.09 0.97
SPCS2 A1 A1 0.92
TPM3 A2 0.9 0.89 0.87 0.96
YWHAB A1 0.89 0.91 0.9 B1
Scores—proteomic results (P) bolded (p<0.05) and non bolded (p<0.01); microarray results (M) with ratio > 1 (A1: p<0.05, A2: p<0.01) and ratio < 1 (B1:
p<0.05, B2: p<0.01). PV/ET—polycythemia vera / JAK2V617F+ essential thrombocythemia ratio, PV/PMF—PV / JAK2V617F+ primary myelofibrosis ratio,
PV / Mut0—PV / JAK2V617F- ET/PMF ratio.
doi:10.1371/journal.pone.0135463.t004
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Fig 4. Expression of genes linked to mTOR signaling pathway in CD34+ cells of MPN origin. A) Up-
regulated genes vs. HuURNA in ET, PV, PMF and ET/PMF subjects without JAK2V617Fmutation (Mut0); B)
Unchanged gene expression vs. HuURNA in ET, PV, PMF and Mut0 subjects; C) Down-regulated genes vs.
HuURNA in ET, PV, PMF and Mut0 subjects analyzed by microarray. Values are mean ± SEM (n = 4–9).
*P < 0.05 compared among MPNs.
doi:10.1371/journal.pone.0135463.g004
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mediated by mTOR [11]. The inhibition of PI3K/AKT/mTOR signaling suppressed the ribo-
somal protein S6 (RPS6) in acute leukemia subjects [28]. RPS6, 70 kDa, polypeptide 2
(RPS6KB2) and PTEN were strongly associated with the activation of the mTOR signaling
pathway in cancer, while mTOR pathway activation demonstrated higher expression of
RPS6K, S6, 4E-BP1 and eIF-4G, linked with more aggressive clinical behavior [29]. The pheno-
typic expression of the cancer genome involved translation by the eIF4E2-directed hypoxic
protein synthesis mechanism [30]. PTEN was generally highly expressed in MPN, according to
Fig 5. mTOR signaling pathway in CD34+ cells of MPN origin. (+p) phosphorylation, (-p) dephosphorylation;! stimulation, ┴ inhibition; white boxes
represent down-regulated genes, gray boxes unchanged genes, black boxes up-regulated genes vs. HuURNA (corresponding to Fig 4), while blue boxes
represent none expressed or sporadically expressed genes in MPNs. GFR—growth factor receptors.
doi:10.1371/journal.pone.0135463.g005
Microarray and Proteomic Analyses of Myeloproliferative Neoplasms
PLOSONE | DOI:10.1371/journal.pone.0135463 August 14, 2015 19 / 23
our results, while RPS6 was down-regulated in JAK2 negative MPNs. EIF4G1 gene expression
was also down-regulated in MPN.
mTOR is a serine/threonine protein kinase that forms two distinct signaling complexes,
mTORC1 and mTORC2, distinguished by their association with Raptor or Rictor, respectively.
Growth factors, as important stimuli of the PI3K and Ras small GTPase pathways, activated
the Akt and ERK serine/threonine kinases, derepressing Ras homolog enriched in brain (Rheb)
and promoting mTORC1 signaling [31]. Rheb stimulated the activation of mTOR with an
essential role in the regulation of S6K and 4EBP1 [32]. In presented results, RHEB gene expres-
sion was decreased, while PTEN increased in CD34+ cells. Tuberous sclerosis proteins 1 and 2
(TSC1/2) complex inhibited mTORC1 signaling through its GAP activity towards Rheb [33].
According to our results, the mTOR activation was stimulated by PI3K/AKT dependent inhibi-
tion of TSC1/2 complex and RHEB. mTOR signaling induced RPS6KA1 gene expression was
also up-regulated by the PI3K/AKT signaling pathway.
Increased erythropoiesis in PV was related to augmented phosphorylation of AKT [34]. It
has been also demonstrated that mTOR regulated proliferation of megakaryocyte progenitors
and the late stages of megakaryocyte differentiation. The mTOR was a critical downstream tar-
get of the thrombopoietin receptor, demonstrating contributions in the proliferation and dif-
ferentiation of normal megakaryocyte cultures [35]. Phosphorylation of mTOR downstream
effectors p70 S6K and 4E-BP1 by thrombopoietin demonstrated PI3K/mTOR dependence
[36]. The increased mTOR phosphorylation has been observed during megakaryopoiesis of
CD34+ cells isolated from ET and PMF subjects, as well as in immunohistochemical analyses
performed on bone marrow samples of ET and PMF subjects [37]. In the presented results,
EIF4EBP1 gene expression was also down-regulated in MPNs, significantly more in PV than
ET subjects.
The co-treatment of dual PI3K/mTOR inhibitor BEZ235 and JAK1/2 inhibitor ruxolitinib
was more effective than single drugs in reducing the degree of disease and prolonging survival
in conditional JAK2V617F knock-in mice [38]. JAK1/2 inhibitor inactivated the mTOR/
p70S6K/4EBP1 pathway and reduced the inhibitory phosphorylation of GSK3 in leukemia cell
line, which correlated with JAK1/2 inhibitor reduction of proliferation and survival of these
cells [39]. PI3K/AKT/mTOR pathway inhibitor everolimus inhibited cell proliferation and clo-
nogenic potential in human JAK2V617Fmutated cell lines. In subjects with PV and PMF,
hematopoietic progenitors were significantly more sensitive to everolimus than healthy control
subjects. A multicenter phase 1/2 trial with everolimus in PMF demonstrated a well-tolerated
clinical efficiency in terms of spleen size reduction and resolution of systemic symptoms and
pruritus [40]. These reports showed that the PI3K/AKT/mTOR pathway may be a new target
for treatment in MPN, in accordance with mTOR’s essential role for expansion of CD34+ cells
during myelopoiesis [41].
In conclusion, investigation of the extent by which common or specific genes participate in
the complex molecular and cellular mechanisms of MPN will lead to new insights of malig-
nancy development. The molecular profiling of CD34+ cells and granulocytes of MPN subjects,
in our study, revealed a gene expression pattern that was not previously recognized in disease
pathogenesis. This profile may be helpful and related to subjects’ clinical characteristics with
imminent prognostic relevance. In addition, our study releases that modulation of the mTOR
signaling pathway may offer a new approach in therapy of MPNs.
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